Epirubicin
Showing 26 - 50 of 709
Breast Tumors Trial in Saint Louis (Doxorubicin, Trastuzumab, Cyclophosphamide)
Terminated
- Breast Neoplasms
- Doxorubicin
- +7 more
-
Saint Louis, MissouriWashington University School of Medicine
Oct 31, 2022
Breast Cancer Trial in Tianjin (Dalcelli?Exemestane?Gosserine, Docetaxel for injection?Epirubicin HCl for
Recruiting
- Breast Cancer
- Dalcelli、Exemestane、Gosserine
- Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection
-
Tianjin, Tianjin, ChinaJie Ge
Aug 20, 2023
Bladder Cancer, Non-muscle Invasive Trial in Biel (Epirubicin, Mitomycin, Gemcitabine)
Recruiting
- Bladder Cancer
- Non-muscle Invasive
- Epirubicin
- +3 more
-
Biel, SwitzerlandRoland Seiler
Nov 17, 2022
Breast Cancer Trial in Shijiazhuang (Dalpiciclib, Aromatase inhibitor, Docetaxel injection)
Recruiting
- Breast Cancer
- Dalpiciclib
- +4 more
-
Shijiazhuang, Hebei, ChinaThe Fourth Hospital of Hebei Medical University
Oct 25, 2023
Diffuse Large B Cell Lymphoma Trial in Shenyang (Zanubrutinib, Rituximab, Cyclophosphamide)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- Zanubrutinib
- +5 more
-
Shenyang, Liaoning, ChinaXing Xiaojing
Jun 1, 2023
Breast Cancer Trial in Houston (Panitumumab, Nab-paclitaxel, Carboplatin)
Completed
- Breast Cancer
- Panitumumab
- +5 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 20, 2022
Breast Cancer Trial in Shanghai (Pegylated liposomal doxorubicin, Epirubicin, Cyclophosphamid)
Recruiting
- Breast Cancer
- Pegylated liposomal doxorubicin
- +5 more
-
Shanghai, ChinaShanghai Pudong Hospital
Dec 11, 2022
Breast Cancer, Neoadjuvant Therapy Trial in Beijing (Utidelone, Carboplatin, Epirubicin)
Not yet recruiting
- Breast Cancer
- Neoadjuvant Therapy
- Utidelone
- +4 more
-
Beijing, Beijing, ChinaCancer Hospital, Chinese Academy of Medical Sciences
Aug 1, 2023
Breast Tumors Trial in Guangzhou (procedure, drug, biological)
Recruiting
- Breast Neoplasms
- Sentinel Lymph Node Biopsy (SLNB)
- +7 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen Memorial Hospital, Sun Yat-sen University
Nov 2, 2023
Breast Cancer Trial in Shenyang (palbociclib combined with letrozole, epirubicin combined with cyclophosphamide and sequential
Not yet recruiting
- Breast Cancer
- palbociclib combined with letrozole
- epirubicin combined with cyclophosphamide and sequential docetaxel
-
Shenyang, Liaoning, ChinaShengjing Hospital of China Medical University
Jul 18, 2021
Hepatocellular Carcinoma Trial in Nanjing (cTACE, Dicycloplatin (TP21), Epirubicin)
Recruiting
- Hepatocellular Carcinoma
- cTACE
- +2 more
-
Nanjing, Jiangsu, ChinaZhongda Hospital, Southeast University
Jul 22, 2022
Breast Tumors Trial in Guangzhou (procedure, drug, biological)
Recruiting
- Breast Neoplasms
- Sentinel Lymph Node Biopsy (SLNB)
- +7 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen Memorial Hospital, Sun Yat-sen University
Jul 31, 2023
Triple Negative Breast Cancer Trial in Shijiazhuang (Albumin bound (nab)-paclitaxel combined with carboplatin followed by
Withdrawn
- Triple Negative Breast Cancer
- Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide
- paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide
-
Shijiazhuang, Hebei, ChinaFourth Hospital of Hebei Medical University
Jul 6, 2021
Breast Cancer Trial in China (Albumin-bound paclitaxel combined with carboplatin, Epirubicin combined with docetaxel)
Recruiting
- Breast Cancer
- Albumin-bound paclitaxel combined with carboplatin
- Epirubicin combined with docetaxel
-
Harbin, Heilongjiang, China
- +6 more
Jul 18, 2021
HER2-negative Breast Cancer, Neoadjuvant Chemo Trial in Hangzhou (Epirubicin, Cyclophosphamid, Docetaxel)
Recruiting
- HER2-negative Breast Cancer
- Neoadjuvant Chemotherapy
- Epirubicin
- +3 more
-
Hangzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Aug 9, 2021
Diffuse Large B-cell Lymphoma Trial in Shanghai (Rituximab, Cyclophosphamide, Epirubicin)
Active, not recruiting
- Diffuse Large B-cell Lymphoma
- Rituximab
- +4 more
-
Shanghai, Shanghai, ChinaShanghai Ruijin Hospital
Dec 1, 2022
Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma Trial in Wuhan (Daratumumab, Carfilzomib,
Recruiting
- Multiple Myeloma
- +2 more
- Daratumumab
- +10 more
-
Wuhan, Hubei, ChinaInstitute of Hematology, Union Hospital, Tongji Medical College,
Nov 18, 2023
HER2 Positive Early Breast Cancer Trial in Shanghai (Docetaxel, carboplatin, Trastuzumab)
Recruiting
- HER2 Positive Early Breast Cancer
- Docetaxel
- +5 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center Shanghai, China, 200032
Jun 6, 2023
HER-2 Positive Breast Cancer Trial in Tianjin (TCbHP VS ddEC-THP)
Recruiting
- HER-2 Positive Breast Cancer
- TCbHP VS ddEC-THP
-
Tianjin, Tianjin, ChinaBreast Oncology, Tianjin Medical University Cancer Institute and
May 15, 2023
Gastric Cancer Trial in Australia, New Zealand (drug, radiation, procedure)
Active, not recruiting
- Gastric Cancer
- Epirubicin + cisplatin + 5-fluorouracil OR epirubicin + cisplatin + capecitabine OR epirubicin + oxaliplatin + capecitabine OR 5-Fluorouracil + leucovorin + oxaliplatin + docetaxel
- +2 more
-
Newcastle, New South Wales, Australia
- +22 more
Mar 21, 2022
Marginal Zone Lymphoma Trial in Zhengzhou (Bortezomib, Rituximab, Epirubicin)
Recruiting
- Marginal Zone Lymphoma
- Bortezomib
- +4 more
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Aug 15, 2021
Peripheral T-cell Lymphoma Targeted Therapy Trial in Tianjin (Azacitidine, Chidamide, Cyclophosphamide)
Enrolling by invitation
- Peripheral T-cell Lymphoma Targeted Therapy
- Azacitidine
- +5 more
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Insititute & Hospital
Jan 9, 2023
Breast Cancer Trial in Sweden (Trastuzumab deruxtecan, Docetaxel, Paclitaxel)
Not yet recruiting
- Breast Cancer
- Trastuzumab deruxtecan
- +9 more
-
Malmö, Sweden
- +6 more
Jun 8, 2023